Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KURA with free AI briefings, catalyst countdowns, and dilution alerts.

KURA · Kura Oncology, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$492.1M Cash on Hand
25.2mo Cash Runway
Follow KURA by email Get an email when KURA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KURA, unsubscribe in one click. Privacy

📣 What KURA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ziftomenib
FDA approved Nov 2025 · Komzifti
Acute Myeloid Leukemia (AML) Phase 3 · NCT07007312 Recruiting
Daunorubicin Acute Myeloid Leukemia (AML) Phase 3 · NCT07007312 Recruiting
Tipifarnib HNSCC Phase 1/2 · NCT04997902 Completed
Pegaspargase Lymphoblastic Leukemia Phase 1/2 · NCT05848687 Recruiting
Mezigdomide KMT2A-rearranged Phase 1 · NCT07355335 Recruiting
Osimertinib NSCLC Phase 1 · NCT05693090 Withdrawn
Darlifarnib Solid Tumors With HRAS Alterations Phase 1 · NCT06026410 Recruiting
Gilteritinib AML Phase 1 · NCT06001788 Recruiting
Fludarabine AML Phase 1 · NCT06001788 Recruiting
Edaxeterkib (KO-947) Advanced Malignant Neoplasm Phase 1 · NCT03051035 Terminated
Gemtuzumab Acute Myeloid Leukemia Phase 1 · NCT06448013 Recruiting
Idarubicin AML Phase 1 · NCT06001788 Recruiting

Also used in these trials (approved or third-party drugs, not KURA's own candidates): Azacitidine, Venetoclax, Cytarabine, Hydroxyurea, Vorinostat, Mitoxantrone, Midazolam Hydrochloride, Methotrexate, Mercaptopurine, Itraconazole, Alpelisib, Blinatumomab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KURA holds $492.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $58.5M/quarter from operations, an estimated runway of 25.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 20 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KURA files for a raise →

👥 Who Owns KURA

Insiders 2.6% Institutions (315 holders) 97.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
Montanova Capital, LLC Institution (13G, 5%+) 8,575,422 9.33% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 7,908,832 8.61% 2026-09-30
BVF PARTNERS L P/IL Institution (13G, 5%+) 6,690,108 7.28% 2026-09-30
STATE STREET CORPORATION Institution (13G, 5%+) 4,931,090 5.37% 2025-12-31
Vanguard Capital Management Institution (13G, 5%+) 4,428,812 4.82% 2026-03-31
Troy Edward Wilson
President and CEO, Director · +1.12M options
Insider 1,414,650 1.54% 2026-11-13
Teresa Brophy Bair
Chief Legal Officer · +100,000 options
Insider 187,002 0.20% 2026-09-28
Thomas Malley
Director · +35,000 options
Insider 149,557 0.16% 2026-03-18
Kathleen Ford
Chief Operating Officer · +100,000 options
Insider 142,986 0.16% 2026-09-28
Thomas James Doyle
SVP, Finance & Accounting · +42,500 options
Insider 142,928 0.16% 2026-09-28
Mollie Leoni
Chief Medical Officer · +100,000 options
Insider 141,095 0.15% 2026-09-28
Brian T. Powl
Chief Commercial Officer · +100,000 options
Insider 136,819 0.15% 2026-09-28

Share count 91,878,694 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-11-30 KOMZIFTI NDA +18.3% -5.8% -1.6%

Browse all historical PDUFA outcomes →

Get the full KURA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KURA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.